What is CGNX's health score?

COGNEX CORP (CGNX) has a TradeApes health score of 57 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is CGNX's estimated fair value?

Based on our 5-year discounted cash flow model, COGNEX CORP's estimated fair value is $8.09 per share, representing a -87.5% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is CGNX undervalued or overvalued?

Our model currently rates CGNX as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for CGNX... Refresh in a moment for the full analysis.

COGNEX CORP (CGNX)

Healthcare Overvalued medium mixed

$64.67

Updated: 2026-06-05

TradeApes Score

Financial Strength

80 Strong

Operating Trend

48 Mixed

Relative Value

38 Weak

Capital Allocation

50 Mixed

Risk

80 Strong

Est. Fair Value $8.09

DCF Upside -87.5%

Sector Rank #3783 of 6835

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.